HAVCR2 and breast carcinoma: Furthermore, our results suggest that the CTLA4-inhibitor ipilimumab, or inhibitors of B7-H3 or TIM-3 that are currently in clinical development (71, 72), may be more effective in combination with ET compared with PD-1 or PD-L1 inhibitors in HR+ breast cancer.